| Summary: | Estimation of current levels of human immunodeficiency virus (HIV) incidence is essential
for monitoring the impact of an epidemic, determining public health priorities,
assessing the impact of interventions and for planning purposes. However, there is
often insufficient data on incidence as compared to prevalence. A direct approach
is to estimate incidence from longitudinal cohort studies. Although this approach
can provide direct and unbiased measure of incidence for settings where the study is
conducted, it is often too expensive and time consuming. An alternative approach is
to estimate incidence from cross sectional survey using biomarkers that distinguish
between recent and non-recent/longstanding infections. The original biomarker based
approach proposes the detection of HIV-1 p24 antigen in the pre-seroconversion period
to identify persons with acute infection for estimating HIV incidence. However,
this approach requires large sample sizes in order to obtain reliable estimates of HIV
incidence because the duration of antigenemia before antibody detection is short,
about 22.5 days. Subsequently, another method that involves dual antibody testing
system was developed. In stage one, a sensitive test is used to diagnose HIV infection
and a less sensitive test such is used in the second stage to distinguish between long
standing infections and recent infections among those who tested positive for HIV
in stage one. The question is: how do we combine this data with other relevant information,
such as the period an individual takes from being undetectable by a less
sensitive test to being detectable, to estimate incidence?
The main objective of this thesis is therefore to develop likelihood based method
that can be used to estimate HIV incidence when data is derived from cross sectional
surveys and the disease classification is achieved by combining two biomarker or
assay tests. The thesis builds on the dual antibody testing approach and extends the
statistical framework that uses the multinomial distribution to derive the maximum
likelihood estimators of HIV incidence for different settings.
In order to improve incidence estimation, we develop a model for estimating HIV
incidence that incorporate information on the previous or past prevalence and derive
maximum likelihood estimators of incidence assuming incidence density is constant
over a specified period. Later, we extend the method to settings where a proportion
of subjects remain non-reactive to a less sensitive test long after seroconversion.
Diagnostic tests used to determine recent infections are prone to errors. To address
this problem, we considered a method that simultaneously makes adjustment for
sensitivity and specificity. In addition, we also showed that sensitivity is similar to
the proportion of subjects who eventually transit the “recent infection” state.
We also relax the assumption of constant incidence density by proposing linear incidence
density to accommodate settings where incidence might be declining or increasing.
We extend the standard adjusted model for estimating incidence to settings where
some subjects who tested positive for HIV antibodies were not tested by a less sensitive
test resulting in missing outcome data. Models for the risk factors (covariates)
of HIV incidence are considered in the last but one chapter. We used data from
Botswana AIDS Impact (BAIS) III of 2008 to illustrate the proposed methods. The
general conclusion and recommendations for future work are provided in the final
chapter. === Theses (Ph.D.)-University of KwaZulu-Natal, Pietermaritzburg, 2013.
|
|---|
